Key result
A systematic review suggests that coxibs should not be prescribed to patients with cardiovascular risk factors due to increased risks of myocardial infarction and stroke.
Why the study?
Do selective cyclooxygenase-2 inhibitors (coxibs) compared to conventional NSAIDs increase the risk of cardiovascular events in gastroenterological high-risk patients?
Systematic Review
Do selective cyclooxygenase-2 inhibitors (coxibs) compared to conventional NSAIDs increase the risk of cardiovascular events in gastroenterological high-risk patients?
Coxibs should be avoided in patients with cardiovascular risk factors due to increased risk of myocardial infarction and stroke; conventional NSAIDs with gastrointestinal protection or acetaminophen are preferred.
Answers are grounded in this paper and cite their sources.
Avoid coxibs in patients with cardiovascular risk; reinforces preference for gastroprotected NSAIDs or acetaminophen in systematic evidence.
Selective cyclooxygenase-2 inhibitors have been marketed as alternatives of conventional, non-steroidal anti-inflammatory drugs with the purpose of reducing/eliminating the risk of ulcer complications. Unexpectedly, randomized-controlled trials revealed that long-term use of coxibs, such as rofecoxib, significantly increased the risk of myocardial infarction and stroke, while the use of valdecoxib was associated with potentially life-threatening skin reactions. Subsequently, rofecoxib and valdecoxib were withdrawn from the market. Although more strict precautions for other coxibs, such as celecoxib, etoricoxib, lumiracoxib and parecoxib, may be accepted/recommended by regulatory agencies, a critical review of published data suggests that their use may not be justified - even in high-risk patients - taking benefits, costs and risks into consideration. Clinicians should, therefore, never prescribe coxibs to patients with cardiovascular risk factors, and should only reluctantly prescribe coxibs to patients with a history of ulcer disease or dyspepsia to overcome persistent pain due to, e.g. rheumatoid arthritis or osteoarthritis. Instead, they should consider using conventional non-steroidal anti-inflammatory drugs in combination with a proton pump inhibitor or a prostaglandin analogue, especially for patients with increased cardiovascular risks, i.e. established ischaemic heart disease, cerebrovascular disease and/or peripheral arterial disease, or alternatively acetaminophen. An evidence-based algorithm for treatment of a chronic arthritis patient with one or more gastrointestinal risk factors is presented.
No takes yet. Share an insight, caveat, or question.
Nielsen et al. (2005) conducted a systematic review in Gastroenterological high-risk patients with chronic arthritis. Coxibs (selective cyclooxygenase-2 inhibitors) vs. Conventional non-steroidal anti-inflammatory drugs was evaluated. A systematic review suggests that coxibs should not be prescribed to patients with cardiovascular risk factors due to increased risks of myocardial infarction and stroke.
Synapse has enriched 10 related papers. Consider them for comparative context: